{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:56:35Z","timestamp":1793318195780,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ8149"],"award-info":[{"award-number":["2024JJ8149"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2025JJ80131"],"award-info":[{"award-number":["2025JJ80131"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108046","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T07:45:22Z","timestamp":1763797522000},"page":"108046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action"],"prefix":"10.1016","volume":"222","author":[{"given":"Bing","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xisha","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.108046_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14740338.2019.1602116","article-title":"An update on the safety of SGLT2 inhibitors","volume":"18","author":"Scheen","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2025.108046_bib2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2025.108046_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib4","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.phrs.2025.108046_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108046_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells12020276","article-title":"Macrophages: from simple phagocyte to an integrative regulatory cell for inflammation and tissue regeneration-a review of the literature","volume":"12","author":"Mamilos","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2025.108046_bib8","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.cell.2022.10.007","article-title":"Macrophages in health and disease","volume":"185","author":"Park","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.108046_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091221","article-title":"Macrophages and foam cells: brief overview of their role, linkage, and targeting potential in atherosclerosis","volume":"9","author":"Poznyak","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2025.108046_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108046_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.108046_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2025.108046_bib13","article-title":"MCL attenuates atherosclerosis by suppressing macrophage ferroptosis via targeting KEAP1\/NRF2 interaction","volume":"69","author":"Luo","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.phrs.2025.108046_bib14","article-title":"Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.108046_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-023-01027-9","article-title":"Macrophage-based therapeutic approaches for cardiovascular diseases","volume":"119","author":"Sansonetti","year":"2024","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.phrs.2025.108046_bib16","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.21037\/tau-21-761","article-title":"Bioinformatics analysis of pathways of renal infiltrating macrophages in different renal disease models","volume":"10","author":"Cheuk","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.phrs.2025.108046_bib17","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.108046_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2025.108046_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21623945.2017.1413516","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization","author":"Xu","year":"2017","journal-title":"Adipocyte"},{"key":"10.1016\/j.phrs.2025.108046_bib20","first-page":"10","article-title":"Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice","author":"Hribal","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.108046_bib21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00424-017-1941-y","article-title":"Macrophages in vascular inflammation and atherosclerosis","volume":"469","author":"Cochain","year":"2017","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"10.1016\/j.phrs.2025.108046_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE\u2212\/\u2212Mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2025.108046_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib24","doi-asserted-by":"crossref","DOI":"10.4070\/kcj.2019.0296","article-title":"Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model","volume":"50","author":"Lee","year":"2020","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.phrs.2025.108046_bib25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/ATVBAHA.121.316233","article-title":"Crosstalk between macrophages and vascular smooth muscle cells in atherosclerotic plaque stability","volume":"42","author":"Yurdagul","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.108046_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.18087\/cardio.2019.4.10254","article-title":"Macrophages and their role in destabilization of an atherosclerotic plaque","volume":"59","author":"Pigarevsky","year":"2019","journal-title":"Kardiologiia"},{"key":"10.1016\/j.phrs.2025.108046_bib27","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00125-021-05498-0","article-title":"Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus","volume":"64","author":"Kohlmorgen","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2025.108046_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.tcm.2010.02.005","article-title":"Mechanisms of cardiac fibrosis in inflammatory heart disease","volume":"19","author":"Kania","year":"2009","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/cvr\/cvt258","article-title":"Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation","volume":"101","author":"Wang","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.phrs.2025.108046_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ajpath.2014.11.027","article-title":"Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis","volume":"185","author":"Falkenham","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2025.108046_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/cvr\/cvu059","article-title":"Cardioprotective function of cardiac macrophages","volume":"102","author":"Fujiu","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib33","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/CIRCULATIONAHA.119.043053","article-title":"Single-Cell reconstruction of progression trajectory reveals intervention principles in pathological cardiac hypertrophy","volume":"141","author":"Ren","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.108046_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1255904","article-title":"Dapagliflozin promotes angiogenesis in hindlimb ischemia mice by inducing M2 macrophage polarization","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2025.108046_bib35","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/s10753-022-01677-2","article-title":"Dapagliflozin alleviates coxsackievirus B3-induced acute viral myocarditis by regulating the macrophage polarization through Stat3-related pathways","volume":"45","author":"Yan","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2025.108046_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41420-024-02247-1","article-title":"Macrophages in organ fibrosis: from pathogenesis to therapeutic targets","volume":"10","author":"Jiang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.phrs.2025.108046_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175729","article-title":"SGLT2 inhibitor dapagliflozin alleviates intramyocardial hemorrhage and adverse ventricular remodeling via suppressing hepcidin in myocardial ischemia-reperfusion injury","volume":"950","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib38","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib39","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.122.062984","article-title":"Single-cell RNA sequencing reveals metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidemia-induced diastolic dysfunction","volume":"150","author":"Panico","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.108046_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02485-z","article-title":"Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling","volume":"20","author":"Lee","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2025.108046_bib41","first-page":"1","article-title":"Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysms by reducing aortic inflammation in mice","volume":"2022","author":"Liu","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2025.108046_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00467-017-3883-1","article-title":"The role of macrophages during acute kidney injury: destruction and repair","volume":"34","author":"Han","year":"2019","journal-title":"Pediatr. Nephrol. (Berl. Ger. )"},{"key":"10.1016\/j.phrs.2025.108046_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-physiol-022516-034219","article-title":"Macrophages in renal injury and repair","volume":"79","author":"Huen","year":"2017","journal-title":"Annu Rev. Physiol."},{"key":"10.1016\/j.phrs.2025.108046_bib44","first-page":"9","article-title":"Long-term treatment with the sodium glucose Cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db Mice","author":"Yagihashi","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.phrs.2025.108046_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1205834","article-title":"Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels","volume":"14","author":"Cai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.108046_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175560","article-title":"Dapagliflozin ameliorates diabetic renal injury through suppressing the self-perpetuating cycle of inflammation mediated by HMGB1 feedback signaling in the kidney","volume":"943","author":"Yuan","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2478\/jtim-2023-0130","article-title":"Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease","volume":"12","author":"Bai","year":"2024","journal-title":"J. Transl. Intern. Med."},{"key":"10.1016\/j.phrs.2025.108046_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biom10111573","article-title":"SGLT2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate","volume":"10","author":"Balzer","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2025.108046_bib49","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00011-023-01796-y","article-title":"SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression","volume":"72","author":"Kim","year":"2023","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10787-023-01227-8","article-title":"Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitis","volume":"32","author":"Makaro","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.phrs.2025.108046_bib51","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","article-title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2025.108046_bib52","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2337\/db16-0049","article-title":"Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism","volume":"65","author":"Briand","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2025.108046_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54224-9","article-title":"Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice","volume":"9","author":"Pennig","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.108046_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2025.108046_bib56","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2147\/JIR.S309427","article-title":"Empagliflozin alleviates atherosclerosis progression by inhibiting inflammation and sympathetic activity in a normoglycemic mouse model","volume":"14","author":"Liu","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13105-023-00974-0","article-title":"The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy","volume":"80","author":"Xu","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/j.phrs.2025.108046_bib58","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1002\/tox.24362","article-title":"Sodium-glucose Co-Transporter-2 inhibitor empagliflozin attenuates sorafenib-induced myocardial inflammation and toxicity","volume":"39","author":"Liu","year":"2024","journal-title":"Environ. Toxicol."},{"key":"10.1016\/j.phrs.2025.108046_bib59","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023800","article-title":"HMGB1-promoted neutrophil extracellular traps contribute to cardiac diastolic dysfunction in mice","volume":"11","author":"Zhang","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2025.108046_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2024.02.006","article-title":"Empagliflozin attenuates inflammation levels in autoimmune myocarditis through the STAT3 pathway and macrophage phenotype transformation","volume":"167","author":"Sheng","year":"2024","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.phrs.2025.108046_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib62","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108046_bib63","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)\u2013Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.108046_bib64","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.phrs.2025.108046_bib66","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.phrs.2025.108046_bib67","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00592-021-01681-2","article-title":"Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy","volume":"58","author":"Castoldi","year":"2021","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2025.108046_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal anti-fibrotic effect of sodium glucose cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2025.108046_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113947","article-title":"Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5\/6-nephrectomy","volume":"156","author":"Lu","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2025.108046_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metabolic Syndrome Clinical Research Reviews"},{"key":"10.1016\/j.phrs.2025.108046_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119481","article-title":"Empagliflozin ameliorates bleomycin-induced pulmonary fibrosis in rats by modulating Sesn2\/AMPK\/Nrf2 signaling and targeting ferroptosis and autophagy","volume":"24","author":"El-Horany","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108046_bib72","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4049\/immunohorizons.2300077","article-title":"Sodium-glucose cotransporter-2 inhibitor, empagliflozin, suppresses the inflammatory immune response to influenza infection","volume":"7","author":"Constantinesco","year":"2023","journal-title":"Immunohorizons"},{"key":"10.1016\/j.phrs.2025.108046_bib73","article-title":"SGLT2 inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice","volume":"25","author":"Lee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.108046_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101646","article-title":"Impact of SGLT-2i on COPD exacerbations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"51","author":"Satapathy","year":"2025","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2025.108046_bib75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/10408363.2024.2361012","article-title":"SGLT2 inhibitors as a potential therapeutic option for pulmonary hypertension: mechanisms and clinical perspectives","volume":"61","author":"Tan","year":"2024","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.phrs.2025.108046_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 Signalling Pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.108046_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1360974","article-title":"Identification of key genes increasing susceptibility to atrial fibrillation in nonalcoholic fatty liver disease and the potential mechanisms: mitochondrial dysfunction and systemic inflammation","volume":"15","author":"Zhong","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2025.108046_bib81","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000783","article-title":"Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet","volume":"7","author":"Xu","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.phrs.2025.108046_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114535","article-title":"The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats","volume":"161","author":"Arag\u00f3n-Herrera","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2025.108046_bib83","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2025.108046_bib84","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1182\/blood-2013-08-520619","article-title":"Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct","volume":"123","author":"Gundra","year":"2014","journal-title":"Blood"},{"issue":"2005","key":"10.1016\/j.phrs.2025.108046_bib85","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.ijo.0803632","article-title":"Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production","volume":"31","author":"Zeyda","year":"2007","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.phrs.2025.108046_bib86","first-page":"e158","article-title":"Tracking hepcidin level in induced type 2 diabetic rats and how Empagliflozin affects its level","volume":"29","author":"Ali","year":"2022","journal-title":"J. Popul. Ther. Clin. Pharmacol. = J. De. la Ther. Des. Popul. Et. De. la Pharmacol. Clin."},{"key":"10.1016\/j.phrs.2025.108046_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320974833","article-title":"Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice","volume":"11","author":"Zhang","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.phrs.2025.108046_bib88","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s12265-023-10390-w","article-title":"The SGLT2 Inhibitor Canagliflozin reduces atherosclerosis by enhancing macrophage autophagy","volume":"16","author":"Chen","year":"2023","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.phrs.2025.108046_bib89","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-019-0454-6","article-title":"Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice","volume":"11","author":"Inoue","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.phrs.2025.108046_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of Type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.phrs.2025.108046_bib91","article-title":"Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation","volume":"45","author":"Tang","year":"2023","journal-title":"Clin. Exp. Hypertens. (N. Y. NY 1993)"},{"key":"10.1016\/j.phrs.2025.108046_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106969","article-title":"Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization","volume":"88","author":"Lin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","article-title":"Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice","volume":"794","author":"Naznin","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2025.108046_bib94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib95","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1042\/BCJ20200278","article-title":"The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice","volume":"477","author":"Steinberg","year":"2020","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2025.108046_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111709","article-title":"Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of Canagliflozin against methotrexate-induced cognitive impairment","volume":"130","author":"Khedr","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib97","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s11357-023-00770-0","article-title":"Four anti-aging drugs and calorie-restricted diet produce parallel effects in fat, brain, muscle, macrophages, and plasma of young mice","volume":"45","author":"Li","year":"2023","journal-title":"GeroScience"},{"key":"10.1016\/j.phrs.2025.108046_bib98","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-\/-) Mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2025.108046_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective Effect of SGLT2 Inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2025.108046_bib100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.phrs.2025.108046_bib101","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement From the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.108046_bib102","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.108046_bib103","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-024-00599-1","article-title":"SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells","volume":"29","author":"Anastasio","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.phrs.2025.108046_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176803","article-title":"Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies","volume":"978","author":"Naeimzadeh","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib105","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s00210-024-03021-x","article-title":"Exploring the therapeutic potential of SGLT2 inhibitors in cancer treatment: integrating in silico and in vitro investigations","volume":"397","author":"Mohite","year":"2024","journal-title":"NaunynSchmiede 's. Arch. Pharmacol."},{"key":"10.1016\/j.phrs.2025.108046_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108468","article-title":"Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk","volume":"37","author":"Hu","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.phrs.2025.108046_bib107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","article-title":"Metabolism, metabolites, and macrophages in cancer","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2025.108046_bib108","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-018-0815-2","article-title":"M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma","volume":"37","author":"Xiao","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108046_bib109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2013.11.013","article-title":"CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF-\u03baB\/FAK pathway","volume":"345","author":"Wang","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2025.108046_bib110","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1172\/JCI23298","article-title":"Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth","volume":"115","author":"Nakao","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2025.108046_bib111","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/annonc\/mdf078","article-title":"Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers","volume":"13","author":"Fujimoto","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.108046_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104119","article-title":"The roles of tumor-associated macrophages in tumor angiogenesis and metastasis","volume":"353","author":"Fu","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.phrs.2025.108046_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102131","article-title":"On the wake of metformin: Do anti-diabetic SGLT2 inhibitors exert anti-aging effects?","volume":"92","author":"Scisciola","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.phrs.2025.108046_bib114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14796678.2024.2433381","article-title":"GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?","volume":"21","author":"Santulli","year":"2024","journal-title":"Future Cardiol."},{"key":"10.1016\/j.phrs.2025.108046_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2023.106479","article-title":"Immunosenescence and macrophages: From basics to therapeutics","volume":"165","author":"Zhu","year":"2023","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2025.108046_bib116","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.108046_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s43587-025-00917-y","article-title":"Characterizing primary and secondary senescence in vivo","author":"Sogabe","year":"2025","journal-title":"Nat. Aging"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:38:26Z","timestamp":1773837506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":117,"alternative-id":["S1043661825004712"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108046","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108046"}}